Abstract Details

Title Harvard Biomarkers Study 2.0: A Longitudinal Multi-modal Platform for Biomarker Discovery in Parkinson’s Disease and Related Disorders

Topic Movement Disorders

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 16-005

Objective To introduce the Harvard Biomarkers Study 2.0 (HBS 2.0), a large-scale, longitudinal, multi-modal resource designed to accelerate biomarker discovery, mechanistic understanding, and precision medicine in Parkinson’s disease (PD) and related synucleinopathies.

Background Accurate diagnosis and disease-tracking in PD remain limited by the absence of validated biomarkers. Building on two decades of the Harvard Biomarkers Study (HBS 1.0), HBS 2.0 expands this landmark natural-history cohort under new leadership to integrate comprehensive clinical, genetic, and biochemical data with cutting-edge analytical approaches.

Design/Methods HBS 2.0 enrolls 2,500 participants (1,000 PD, 1,000 other neurodegenerative diseases, 500 controls) with baseline and seven annual follow-ups. Data include standardized motor, cognitive, autonomic, and olfactory assessments; blood, saliva, and optional CSF sampling; wearable sensor and telehealth modules; and linkage to other MGB-directed studies (MyTrial, CLIMB, Kneu Health). Integration of legacy HBS 1.0 datasets into a unified REDCap/i2b2 infrastructure enables harmonized querying and cross-study interoperability. Additionally, biochemical pipelines include optimization of quantitative α-synuclein seed amplification assays (SAA) in plasma and neuronal models. Lastly, genomic analyses leverage rare-variant association frameworks (SKAT-O, NERINE) to identify genetic determinants of progression.

Results Harmonization and database development have achieved full alignment of HBS 1.0 and HBS 2.0 variables. This allowed us to conduct slope analyses of UPDRS and MMSE trajectories, delineating fast versus slow progressors, and supporting downstream genotype–phenotype association testing. Biochemically, pilot SAA and immunoprecipitation methods demonstrate improved specificity for α-synuclein seed detection in plasma. While, genomically, preliminary NERINE analyses highlight autophagy and vesicle-trafficking modules as enriched for PD-associated rare variants.

Conclusions HBS 2.0 represents one of the world’s most comprehensive PD biorepositories, integrating longitudinal clinical, genetic, and biospecimen data. Its open-science infrastructure and methodological innovations establish a powerful platform for biomarker discovery, mechanistic insight, and future clinical-trial readiness in PD and related disorders.

Authors/Disclosures
Daniel N. El Kodsi, PhD PRESENTER	Dr. El Kodsi has nothing to disclose.
Diego Rodriguez, Sr., MD	No disclosure on file
Olivia Laun	Ms. Laun has nothing to disclose.
Breelyn Gilbert	Miss Gilbert has nothing to disclose.
Vikrant Rai, MBBS, PhD	Dr. Rai has nothing to disclose.
Anya P. Gemos, Research Assistant	Miss Gemos has nothing to disclose.
Evrim Sude Con, Undergraduate Student	Ms. Con has nothing to disclose.
Ariv Vaidya, High schooler	Mr. Vaidya has nothing to disclose.
Habib Nasir, BS	Mr. Nasir has nothing to disclose.
Sumaiya Nazeen, PhD	Dr. Nazeen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dacapo Brainscience, Inc..
Anastasia Kuzkina, MD	Dr. Kuzkina has nothing to disclose.
Inmaculada Barrasa, PhD	Dr. Barrasa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Robigo.
Vikram Khurana, MD, PhD (Kings County Hospital)	Dr. Khurana has received personal compensation for serving as an employee of DaCapo BrainScience. An immediate family member of Dr. Khurana has received personal compensation for serving as an employee of Arbor Therapeutics. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda Pharmaceuticals. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Khurana has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DaCapo Brainscience. Dr. Khurana has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Mission MSA. Dr. Khurana has stock in DaCapo Brainscience. The institution of Dr. Khurana has received research support from Sanofi. The institution of Dr. Khurana has received research support from Janssen. The institution of Dr. Khurana has received research support from Biohaven. The institution of Dr. Khurana has received research support from Tiziana Life Sciences. Dr. Khurana has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��